The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1511
January 2, 2017
View Complete Issue         Table of Contents 2019 
Another Insulin Glargine (Basaglar) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Another Insulin Glargine (Basaglar) for Diabetes
January 2, 2017 (Issue: 1511)
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Insulin Glargine (Basaglar) for Diabetes
Article code: 1511b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.